MedTrace Logo

LRFN5 and OLFM4 in Schizophrenia

NCT07434388 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-02-25

No results posted yet for this study

Summary

This cross-sectional observational study evaluated serum levels of Leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and Olfactomedin-4 (OLFM4) in patients with schizophrenia during acute exacerbation and in healthy controls. The study also assessed associations between these biomarkers and clinical symptom severity, global functioning, and systemic inflammation measured by the Aggregate Index of Systemic Inflammation (AISI). The study aimed to investigate convergent synaptic and immunoinflammatory dysregulation in schizophrenia.

Conditions

  • Schizophrenia Disorder

Sponsors & Collaborators

  • Elazığ Mental Health and Diseases Hospital

    lead OTHER_GOV

Principal Investigators

  • Mehmet Hamdi ÖRÜM, MD · Elazığ Mental Health and Diseases Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-27
Primary Completion
2025-12-01
Completion
2025-12-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07434388 on ClinicalTrials.gov